Markers for step-down of inhaled corticosteroid therapy in adult asthmatics

Allergology International

Volumn 61, Issue 3, 2012, Pages 419-429

  Tsurikisawa, Naomi ^a   Oshikata, Chiyako ^a   Tsuburai, Takahiro ^a   Mitsui, Chihiro ^a   Tanimoto, Hidenori ^a   Takahashi, Kentaro ^a   Sekiya, Kiyoshi ^a   Nakazawa, Takuya ^a   Minoguchi, Kenji ^a   Otomo, Mamoru ^a   Maeda, Yuji ^a   Saito, Hiroshi ^a   Akiyama, Kazuo ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

Adult asthma; Airway hyperresponsiveness; Asthma management; ICS; Step down

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; BRONCHIAL PROVOCATION TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NITRIC OXIDE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84867792272     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.11-OA-0402     Document Type: Article

References (45)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Revised 2006. Available from: http://www.ginasthma.org/.
2. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003;326:1115-1120.
3. Powell H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. Thorax 2004;59:1041-1045.
4. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2004; (2): CD004109.
5. Boulet LP, Drollmann A, Magyar P et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006;100:785-794.
6. Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004;9:528-534.
7. Bateman ED, Fairall L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res 2006;7:13-22.
8. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006;117:563-570.
9. Godard P, Greillier P, Pigearias B, Nachbaur G, Desfougeres JL, Attali V. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomized study. Respir Med 2008; 102:1124-1131.
10. Koenig SM, Ostrom N, Pearlman D et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg discus are "steppeddown". J Asthma 2008;45:681-687.
11. Rimington LD, Davies DH, Lowe D, Pearson MG. Relationship between anxiety, depression, and morbidity in adult asthma patients. Thorax 2001;56:266-271.
12. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352: 2163-2173.
13. Shaw DE, Berry MA, Thomas M et al. The use of exhaled nitric oxide to guide asthma management. A randomized control trial. Am J Respir Crit Care Med 2007;176:231-237.
14. Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest 2008;134: 733-739.
15. Leuppi JD, Salome CM, Jenkins CR et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001;163:406-412.
16. Foresi A, Mastropasqua B, Chetta A et al. Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma. Chest 2005;127:117-124.
17. Jayaram L, Pizzichini MM, Cook RJ et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-494.
18. Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 1991;87:483-489.
19. Clearie KL, Jackson CM, Fardon TC et al. Supervised step-down of inhaled corticosteroids in the community, an observational study. Respir Med 2011;105:558-565.
20. McKinlay L, Williamson PA, Short PM, Fardon TC, Lipworth BJ. Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma. Br J Clin Pharmacol 2010;71:128-131.
21. Tsurikisawa N, Tsuburai T, Oshikata C et al. Prognosis of adult asthma after normalization of bronchial hyperresponsiveness by inhaled corticosteroid therapy. J Asthma 2008;45:445-451.
22. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244.
23. Hansel FK. On the Hansel stain. Ann Allergy 1977;39:142.
24. Solley GO, Gleich GJ, Jordon RE, Schroeter AL. The late phase of the immediate wheal and flare skin reaction. J Clin Invest 1976;58:408-420.
25. Crapo RO, Casaburi R, Coates AL et al. Guidelines for methacholine and exercise challenge testing 1999. Am J Respir Crit Care Med 2000;161:309-329.
26. Tsuburai T, Tsurikisawa N, Taniguchi M et al. The relationship between exhaled nitric oxide measured with an off-line method and airway reversible obstruction in Japanese adults with asthma. Allergol Int 2007;56:37-43.
27. Sposato B, Pammolli A, Bove L et al. A regular or an intermittent treatment for asthma: the long-term effect. Eur Rev Med Pharmacol Sci 2010;14:1037-1044.
28. Dinakar C. Update on asthma step-therapy. Allergy Asthma Proc 2010;31:444-451.
29. Benayoun L, Druihe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167: 1360-1368.
30. Siddiqui S, Mistry V, Doe C et al. Airway hyperresponsiveness is dissociated from airway wall structural remodelling. J Allergy Clin Immunol 2008;122:335-341.
31. James AL, Maxwell PS, Pearce-Pinto G, Elliot JG, Carroll NG. The relationship of reticular basement membrane thickness to airway wall remodeling in asthma. Am J Respir Crit Care Med 2002;166:1590-1595.
32. Chetta A, Foresi A, Donno MD et al. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am J Respir Crit Care Med 1996;153:910-917.
33. Pepe C, Foley S, Shannon J et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005;116:544-549.
34. Pascual RM, Peters SP. Airway remodelling contributes to the progressive loss of lung function in asthma: An overview. J Allergy Clin Immunol 2005;116:477-486.
35. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160: 1001-1008.
36. Tsurikisawa N, Oshikata C, Tsuburai T et al. Bronchial hyperresponsiveness to histamine correlates with airway remodeling in adults with asthma. Res Med 2010;104: 1271-1277.
37. Amin K, Ludviksdottir D, Janson C et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. Am J Respir Crit Care Med 2000;162:2295-2301.
38. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax 1981;36:575-579.
39. Lin S, Jatakanon A, John M et al. Effect of inhaled budesonide on lung function and airway inflammation. Am J Respir Crit Care Med 1999;159:22-30.
40. Dupont LJ, Rochette F, Demedts MG, Verleden GM. Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma. Am J Respir Crit Care Med 1998;157:894-898.
41. Tsuburai T, Tsurikisawa N, Tatsuno S et al. Changes in exhaled nitric oxide measured by two offline methods predict improvements in bronchial hyperresponsiveness after inhaled steroid therapy in Japanese adults with asthma. Allergol Int 2009;58:537-542.
42. Tsurikisawa N, Oshikata C, Tsuburai T et al. Bronchial reactivity to histamine is correlated with airway remodeling in adults with moderate to severe asthma. J Asthma 2010; 47:841-848.
43. Oshikata C, Tsuburai T, Tsurikisawa N et al. [The cutoff point of the fraction of exhaled nitric oxide (FeNO) with the off-line method for diagnosing asthma and the effect of smoking on FeNO]. Nihon Kokyuki Gakkai Zasshi 2008;46:356-62 (in Japanese).
44. Japanese Society of Allergology. [Japanese Guideline for The Diagnosis and Treatment of Allergic Diseases 2010]. Tokyo: Kyowa Kikaku, 2010;54-58 (in Japanese).
45. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19-24.